Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

NCT06100497 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Pembrolizumab
DRUG: Cisplatin
DRUG: Paclitaxel-albumin

Sponsor

Beijing Tongren Hospital